Pitcairn’s Harmony Biosciences HRMY Stock Holding History

Pitcairn’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,975	Closed	-$210K	–	663
2023 Q2	$210K	Buy	+5,975	New	+$206K	0.02%	609

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Pitcairn's HRMY Position: Q3 2023 in Review

Pitcairn sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 5,975 shares — an estimated $210K sold.

Pitcairn first reported a position in HRMY in Q2 2023 and held it in 1 quarter. The position peaked at $210K in Q2 2023. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

Pitcairn reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
Pitcairn sold 5,975 Harmony Biosciences shares in Q3 2023, an estimated $210K.
Pitcairn first reported a position in Harmony Biosciences in Q2 2023 and held it in 1 quarter.
Pitcairn's Harmony Biosciences position peaked at $210K in Q2 2023.
204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on Pitcairn's 13F filing for Q3 2023, filed 13 Nov 2023.